StockNews.com started coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) in a research note issued to investors on Monday. The firm set a "hold" rating on the stock.
Tonix Pharmaceuticals Stock Performance
TNXP traded down $0.21 on Monday, hitting $0.40. 192,571,672 shares of the company traded hands, compared to its average volume of 29,835,520. The company has a 50 day moving average of $0.21 and a 200-day moving average of $0.41. Tonix Pharmaceuticals has a 12-month low of $0.12 and a 12-month high of $14.08. The stock has a market capitalization of $75.34 million, a PE ratio of -0.01 and a beta of 2.23. The company has a quick ratio of 2.81, a current ratio of 3.33 and a debt-to-equity ratio of 0.07.
Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($2.03) by $1.80. The business had revenue of $2.82 million during the quarter, compared to analysts' expectations of $2.63 million. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. Sell-side analysts anticipate that Tonix Pharmaceuticals will post -17.63 earnings per share for the current year.
About Tonix Pharmaceuticals
(
Get Free Report)
Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.
Recommended Stories
Before you consider Tonix Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tonix Pharmaceuticals wasn't on the list.
While Tonix Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
